NCT04665154View on ClinicalTrials.gov

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 7, 2019

Primary Completion Date

August 3, 2022

Study Completion Date

August 3, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

MAS825

single dose i.v. and s.c.

DRUG

Placebo

single dose i.v. and s.c.

Trial Locations (3)

66211

Novartis Investigative Site, Overland Park

85283

Novartis Investigative Site, Tempe

NG11 6JS

Novartis Investigative Site, Mere Way

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY